Freeslate integrates the DropSense96TM for Biologics Quantification on its Biologics Formulation System
Sunnyvale, California USA and Gentbrugge, Belgium: 19 January 2015 -Freeslate Inc, the leading provider of high throughput research solutions for biopharmaceutical development, and Trinean NV, the leading provider of microfluidic spectrophotometry platforms, today announced the integration of the DropSense96TM with the CM3 product line for biotherapeutics formulation and optimization.
Based on the CM3 automation platform, the Freeslate Biologics Formulation System offers high throughput formulation, stressing, and analysis. Integration of the DropSense96TM provides CM3 users the ability to quickly determine protein concentration without dilution steps. This increases system accuracy and results in faster workflows.
Next > FEops closes a € 1.3M series A financing round to commercialise its TAVIguide™ service
Previous > UK Biobank selects Trinean’s DropSense96TM for DNA quantitation throughout its Genotyping project